Syllabus · Current · V5 (2025) · Endocrine System

L2 · Endocrine Pharmacology

L2.iii · Hypoglycaemic Drugs

Official V5 objective
Understand the pharmacology of hypoglycaemic drugs.
3 SAQ topics 4 SAQ appearances 4 VIVA stations

Written examination

SAQ history

4 appearances
Classify the oral hypoglycaemic drugs (20% marks); include their mechanism of action (40% marks) and their most significant side effects (40% marks).
37%
Classify the oral hypoglycaemic drugs; include their mechanism of action, and their most significant side effects.
Outline the mechanisms of action and adverse effects of the following: (a) Biguanides (35% of marks). (b) Sodium-Glucose cotransporter – 2 (SGLT-2) inhibitors (SGLT-2) (35% of marks). (c) Sulfonylureas (30% of marks).
52%
Short-acting Insulin
1 exam appearance
Describe the pharmacology of short acting insulin (actrapid).

Oral examination

VIVA history

4 stations

Sources: objective text from the relevant CICM syllabus; historical SAQ and VIVA wording from CICM examiner reports.